Subconjunctival liposomal sirolimus vs. cyclosporine or tacrolimus as treatment of keratoconjunctivitis sicca in dogs: A double‐blind, randomized study

• Published in: Veterinary ophthalmology 2024-09, Vol.27 (5), p.461-468
• Main Authors: García‐Santisteban, Rodrigo, Linares‐Alba, Mónica Anayatzin, Botello‐Bárcenas, Andrés, Margay, Paola, Soto, Carlos, Fonzar‐Furtado, Joice, Brooks, Dennis, García, Diego, Sánchez, Gustavo Adolfo García
• Format: Article
• Language: English
• Subjects: Animals; Cyclosporine - administration & dosage; Cyclosporine - therapeutic use; Dog Diseases - drug therapy; Dogs; Double-Blind Method; dry eye; Female; Immunosuppressive Agents - administration & dosage; Immunosuppressive Agents - therapeutic use; Keratoconjunctivitis Sicca - drug therapy; Keratoconjunctivitis Sicca - veterinary; Liposomes; Male; nanotechnology; Sirolimus; Sirolimus - administration & dosage; Sirolimus - therapeutic use; Tacrolimus - administration & dosage; Tacrolimus - therapeutic use; Treatment Outcome
• ISSN: 1463-5216; 1463-5224; 1463-5224
• DOI: 10.1111/vop.13190

Purpose To compare the safety and efficacy of a 100 microgram subconjunctival injection of liposome‐encapsulated sirolimus (SCJS) to cyclosporine (CsA) or tacrolimus (CsA/T) for the treatment of keratoconjunctivitis sicca (KCS) in dogs. Methods Dogs with signs and symptoms of KCS were block‐randomized to one of two treatment groups: Biweekly SCJS or conventional treatment (CsA/T). Schirmer tear test 1 (STT‐1) scores, conjunctival hyperemia (CH) scores, corneal opacity (CO) scores, and clinical evaluation of potential side effects were recorded every 2 weeks for 14 weeks for both groups. Differences between groups were analyzed using the mixed results ANOVA and U‐Mann Whitney tests (p